Cimivir L Tablets

Product Description

Exporters & Suppliers of Cimivir L Tablets Price in India 

CIMIVIR-L™, a once-a-day oral therapy, will offer a convenient, effective and safe alternative
to people infected with the Hepatitis-C virus (HCV). It is estimated that nearly one lakh people die annually in India from HCV infection and co-morbidities. CIMIVIR-L™ is indicated for Hepatitis-C Genotype 1 patients who account for ~25% of the total estimated HCV patient population of 18 million in the country.
Hepatitis C is a viral disease that causes liver inflammation leading to diminished liver function or liver failure.
It is referred to as a “silent epidemic” as most people infected with HCV have no symptoms of the disease until liver damage becomes apparent, which
may take decades. Chronic HCV infection could lead to scarring and poor liver function (cirrhosis) over many years, resulting in complications such as bleeding, jaundice, fluid accumulation in the abdomen, infections and liver cancer.

Hepatitis C is a global public health concern and lack of disease awareness and unavailability of treatment options are the main factors limiting disease management in developing economies like India.
Previous treatment regimens for Hepatitis-C Genotype 1 often involved multiple separate medicines and complicated dosing, which were largely difficult to tolerate.

CIMIVIR-L TABLET For Hepatitis Patients

A once-a-day pill treatment, CIMIVIR-L™ not only offers convenience but also better cure rates and patient tolerance compared to existing therapies.
Clinical studies by the innovator on a wide range of chronic HCV patients have shown that the Sofosbuvir-Ledipasvir combination-therapy resulted in very high cure rates ranging from 94% -99%*. ( see notes to the editor)Biocon, which had launched CIMIVIR™ (Sofosbuvir) earlier in 2015, has been working towards raising awareness about HCV in India and improve the diagnosis of the disease in the country.